Answering Your Coronavirus Questions
Akiko Iwasaki, PhD, Waldemar Von Zedtwitz Professor of Immunobiology and Molecular, Cellular and Developmental Biology; and professor of molecular, cellular, and developmental biology, answers questions about the 2019 novel coronavirus from channel 3's Kara Sundlun.Source: WFSB Channel 3
Yale Cancer Center scientist urges widespread HPV vaccinations
It’s a two-shot vaccination that helps prevent six types of cancer. The vaccine prevents infection by the human papillomavirus, the most common sexually transmitted infection, 95 percent of the time, said Linda Niccolai, a professor of epidemiology at the Yale School of Public Health and an associate of the Yale Cancer Center.Source: New Haven Register
Yale Cancer Center Partners in Fight to Help Eliminate HPV-related Cancers
Yale Cancer Center joins the Association of American Cancer Institutes (AACI) and its partner organizations to endorse a Call to Action for our nation to work together toward the elimination of human papillomavirus (HPV)-related cancers.
Iwasaki Is Honored by the International Cytokine & Interferon Society
Akiko Iwasaki, PhD, Waldemar Von Zedtwitz Profesor of Immunobiology and Molecular, Cellular, and Developmental Biology; and professor of dermatology, is a 2019 recipient of the Seymour & Vivian Milstein Award for Excellence in Interferon and Cytokine Research, given by the International Cytokine & Interferon Society (ICIS).
Antiretroviral Therapy Crucial in Preventing non-Hodgkin Lymphoma, YSPH Study Reinforces
A research team led by the Yale School of Public Health has found that for people living with HIV/AIDS, both recent immunosuppression and prolonged HIV viremia play important and independent roles in the development of non-Hodgkin lymphoma.
Discovery may help provide clues for fighting and treating HPV
Yale Cancer Center (YCC) scientists have filled in a key gap in understanding the unusual route by which the Human papillomavirus (HPV) infects cells. Their findings, published online today in the journal Cell, may eventually help to broaden the scope of defenses against HPV and provide valuable clues for delivering drugs into cells. HPV is a family of killers. Although there are effective vaccines against these viruses, they still cause about 5% of cancer deaths worldwide, including more than 250,000 women who die of cervical cancer each year.
Yale enhances its cytometry capabilities
The methods and equipment used to probe cellular questions are rapidly advancing—including, at Yale, through the addition in 2014 of CyTOF, or Cytometry Time-Of-Flight, and this past June of the CyTOF Imaging Mass Cytometer (IMC), which greatly expands Yale's ability to examine specimens that are analyzed both for clinical diagnosis and for basic research.Source: Medicine@Yale
Opportunities to vaccinate young women against HPV missed at alarming rate
en aged 18-26 who were eligible to receive Human Papilloma Virus (HPV) vaccine have missed at least one opportunity to receive the vaccine during a visit to an obstetrics and gynecology clinic, Yale researchers report. This study also confirms previous research showing racial disparities in vaccination for HPV: Women who identify as black are 61% more likely have had a missed opportunity than women who identify as white. These findings are published in the American Journal of Obstetrics and Gynecology. HPV is a well-known cause of pre-cancerous cervical lesions, which, if untreated, could develop into cervical cancer. Immunization against HPV has been shown to be safe and effective in preventing these pre-cancerous lesions. The two-dose HPV vaccine is recommended for administration to It is recommended that girls ages 11-12 receive the two-dose HPV vaccine, and that those through age 26 receive the three-dose vaccination for “catch-up.”
Public Health in Connecticut–Racial Disparities a Persistent Issue
Connecticut is the fourth richest state in the country and the third healthiest. Nevertheless, it still has three very poor cities where health disparities among minorities are reflected in health statistics across the board, said Dr. Raul Pino, commissioner of the Connecticut Department of Public Health (DPH).
HIV-related Cancers Dropped Thanks to ART
Certain cancer risks in HIV patients in the US have been reduced due to the emergence of antiretroviral therapies (ART) in the last 20 years. A new study has found that several virus-related cancers, as well as lung cancer, have declined in risk since 1996 — when ART was expanded in HIV therapy regimens. The result is an indication of improved patient care, as well as a change in the prevalence of risk factors caused by HIV patients. Particular cancers, including Kaposi sarcoma, lymphomas, and cervical, anal, and liver cancers, have been known to have an elevated presence in HIV patients for a long time, study lead author Raul Hernandez-Ramirez, MSc, told MD Magazine.Source: MD Magazine
Men's Risk for HPV-Related Oral Cancer Soars
Human papillomavirus, the highly prevalent sexually transmitted infection, is like Amtrak on Thanksgiving -- it comes with a lot of baggage. We associate HPV with cervical cancer, but somewhere between 2008 and 2012, oropharyngeal cancer overtook cervical cancer as the most common HPV-associated malignancy. We used to associate oropharyngeal cancer with smoking, but the epidemiology demonstrates that in the modern era oropharyngeal cancer is really driven by HPV.Source: MedPage Today
$1.8 Million Granted to Yale School of Public Health to Study Effectiveness of HPV Vaccine
A $1.8 million National Institutes of Health grant will help researchers at the Yale School of Public Health shed light on the real-world effectiveness of the Human Papillomavirus (HPV) vaccine. Results of this study can ultimately help to maximize the vaccine’s impact on several types of cancer.
Precancerous Lesions Associated with HPV Dropping in Connecticut, YSPH Study Finds
The vaccine for the Human Papillomavirus (HPV) is proving to have significant population-level effects in Connecticut, with rates of precancerous lesions caused by HPV down drastically among young women, a new Yale School of Public Health study finds.
NCI-designated Cancer Centers Endorse Updated HPV Vaccination Recommendations
Recognizing a critical need to improve national vaccination rates for the human papillomavirus (HPV), Yale Cancer Center has again united with each of the 69 National Cancer Institute (NCI)-designated cancer centers in issuing a joint statement in support of recently revised recommendations from the Centers for Disease Control and Prevention (CDC).
American Cancer Society Approves New Research and Training Grants at Yale University
The American Cancer Society (ACS), the largest non-government, not-for-profit funding source of cancer research in the United States, has approved funding for three new research grants totaling over $1.7 million to investigators at Yale University. These grants are among 11 new projects in effect across New England as of January 1, 2017 totaling more than $4.4 million dollars.
Are You Addicted to the Sun?
Women, especially those with lighter skin, tend to have a higher risk of developing tanning dependence than men do, researchers say. And "the younger you are when you start tanning, the more likely you are to later have a problem with it," says Dr. Bryon Adinoff, a professor of psychiatry at the UT Southwestern Medical Center in Dallas. There also may be a hereditary component: A 2014 study from the Yale School of Public Health and the Yale Cancer Center found that people who carry a particular variant in the PTCHD2 gene may be more likely to develop an addiction to tanning.Source: U.S. News & World Report